First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASHnoodls Dec 7
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 7, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from an ad hoc analysis of a ...
As investors look back at 2013, some of the most compelling lessons for succeeding in treating rare disease have been taught by BioMarin.
Catch up on Jim Cramer's thinking over the past week on where to buy in 2014.
It might be cold outside, but OncoMed, Puma, and Aerie are sizzling hot.
Celgene's sotatercept gets FDA orphan designation
Celgene (CELG) is making strikingly creative deals to keep pipelines filled with promising therapies, including Celgene's most recent partnership with stem cell player OncoMed (ONCO).
Here are four more themes where you can put money to work.
Cramer disagrees with the downgrade of Agnico-Eagle Mines but agrees with the call on Cheniere Energy.
Trade-Ideas LLC identified Celgene Corporation (CELG) as a new lifetime high candidate
The trading panel discussed whether bonds will decline if the jobs numbers are strong.
Celgene (CELG), Biogen (BIIB), and Amgen (AMGN) all have blockbuster drugs kicking in billions of revenue. But, is one better than the other at turning that cash into profit?
4 Potential Blockbuster Drugs Awaiting Launch
Celgene advances following UBS upgrade to Buy
Celgene Corporation was a winner within the drugs industry, rising $4.44 (2.8%) to $164.51 on average volume